ArticleMedicine2017

Immune-related adverse events associated with PD-1 and PD-L1 inhibitors for nonsmall cell lung cancer: Protocol for a systematic review and meta-analysis.

Xiaoying Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.